Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.
复制标题
DOI：
10.3748/wjg.v22.i34.7727
复制
发表时间：
2016-09-14
影响因子：
4.3
通讯作者：
Bessissow T
中科院分区：
文献类型：
--
作者：
Chao CY;Battat R;Al Khoury A;Restellini S;Sebastiani G;Bessissow T
新出现的数据强调了非酒精性脂肪肝（NAFLD）和炎症性肠病的共存;这两种疾病都越来越普遍，并发症严重，对未来的健康负担有影响。横断面观察性研究显示，共存疾病的患病率差异很大，主要是由于研究中使用的疾病定义和诊断工具的差异。年龄、肥胖、胰岛素抵抗和其他代谢状况是观察性研究中常见的风险因素。然而，其他研究也表明，炎症性肠病相关因素（如疾病活动度、持续时间、类固醇使用和既往手术干预）在NAFLD的发展中起着更主导的作用。这表明这两种疾病之间可能存在更复杂的发病机制和关系，这可能是由包括肠道通透性改变、肠道生态失调和慢性炎症反应在内的因素造成的。常用的免疫调节剂具有潜在的肝毒性，但没有明确的证据表明它们与肝脂肪变性的发生有关，也没有任何数据表明治疗和预后对并存疾病患者的影响。需要进一步的研究来评估影响，并建立适当的筛查和管理策略，以便早期识别，干预和改善患者的结果。
Emerging data have highlighted the co-existence of non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent disorders with significant complications and impact on future health burden. Cross-section observational studies have shown widely variable prevalence rates of co-existing disease, largely due to differences in disease definition and diagnostic tools utilised in the studies. Age, obesity, insulin resistance and other metabolic conditions are common risks factors in observational studies. However, other studies have also suggested a more dominant role of inflammatory bowel disease related factors such as disease activity, duration, steroid use and prior surgical intervention, in the development of NAFLD. This suggests a potentially more complex pathogenesis and relationship between the two diseases which may be contributed by factors including altered intestinal permeability, gut dysbiosis and chronic inflammatory response. Commonly used immunomodulation agents pose potential hepatic toxicity, however no definitive evidence exist linking them to the development of hepatic steatosis, nor are there any data on the impact of therapy and prognosis in patient with co-existent diseases. Further studies are required to assess the impact and establish appropriate screening and management strategies in order to allow early identification, intervention and improve patient outcomes.
登录
查看更多内容
影响因子：
2.2
作者：
Hubel, J. M.;Schmidt, S. A.;Flechtner-Mors, M.
通讯作者：
Flechtner-Mors, M.
影响因子：
--
作者：
Cappello, Maria;Randazzo, Claudia;Almasio, Piero Luigi
通讯作者：
Almasio, Piero Luigi
影响因子：
8
作者：
Dignass, A.;Van Assche, G.;Travis, S. P. L.
通讯作者：
Travis, S. P. L.
影响因子：
4.1
作者：
Dolinsky, VW;Douglas, DN;Vance, DE
通讯作者：
Vance, DE
影响因子：
8.2
作者：
通讯作者：
--